132 trends tracked about this subject — the full history, oldest to newest below.
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk raises its 2026 outlook and shares surge as the Wegovy weight-loss pill rollout accelerates.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pfizer CEO touts massive deal volume and a raised profit forecast amid strong quarterly earnings reports.
Pfizer raises its full-year outlook and beats Q3 expectations as it pivots toward cancer and weight-loss medications in a post-pandemic recovery.
Pfizer has increased its 2026 full-year guidance following strong third-quarter results driven by growth in cancer and migraine medications.
A promising new HIV-prevention drug is facing significant accessibility challenges in regions where it is most needed, including parts of Africa.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly reports that its new drug, retatrutide, achieved more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
Missouri's Attorney General issues a cease-and-desist letter to drug manufacturer Eli Lilly over a contested pricing policy.
6 news sources are covering this World story right now — PULSE is tracking how fast it spreads.
GSK anticipates its oncology clinical pipeline will nearly double in 2027 following an aggressive period of dealmaking and strategic acquisitions.
A US judge has ruled against Novo Nordisk, allowing Eli Lilly to continue running advertisements for its weight-loss medications.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Federal regulators and state authorities allege Martin Shkreli violated a lifetime pharmaceutical industry ban.
Early research indicates GLP-1 weight-loss drugs may slow biological aging by up to four years, according to recent coverage.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
A simple daily pill met its goals in a late-stage trial, raising prospects for halting Parkinson's disease before onset.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Viatris is expanding its innovative medicines strategy by acquiring Pacira BioSciences for $1.65 billion to lead in non-opioid pain therapies.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
The pharmaceutical lobby group has launched a lawsuit against the Trump administration over most favored nation drug pricing policies.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Novartis strikes a massive licensing agreement worth up to $7.8 billion with China-based biotech firm Abogen.
The U.S. government is pushing to reshore the production of essential medicines amid new tariffs, while India's dominant role complicates these goals.
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
An experimental combination drug from Eli Lilly outperforms Zepbound in a new weight-loss trial.
Eli Lilly's experimental triple agonist drug retatrutide demonstrates significant weight loss and A1C reduction in recent clinical trials.
Eric Cantor, the former House majority leader, has been selected as the new president and chief executive officer of PhRMA.
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
Recent breakthroughs in immunology and new pharmaceutical frontiers are shifting the approach to treating Alzheimer's disease.
Medical and lifestyle experts are questioning the long-term safety and efficacy of GLP-1 medications as they transition from clinical tools to consumer drugs.
The FDA has issued a nationwide recall for over 13,000 bottles of Chlorthalidone blood pressure medication following failed dissolution testing.
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
A Canadian study warns that common drug combinations are triggering harmful prescribing cascades in older adults, risking their health and independence.
GLP-1 medications face growing attention for unexpected health benefits and wider usage trends beyond weight management.
AstraZeneca's breast cancer pill Etcamah missed its primary goal in a late-stage trial, adding to oral SERD failures.
Recent coverage examines inappropriate prescribing cascades where older adults receive new medications to treat side effects.
The failure of heart drug trials from pharmaceutical giants Novartis and Novo Nordisk creates a significant setback for a promising field of medicine.
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
A major Novartis shareholder is demanding a board overhaul following a series of costly drug trial setbacks and strategic failures.
Recent coverage explores potential links between a lung disease drug and the slowing of biological aging.
Takeda has released Phase 3 study data for oveporexton, a new drug designed to treat the excessive daytime sleepiness associated with narcolepsy.
Novartis is facing significant scrutiny within the biotech sector following a series of dual failures that have impacted investor confidence.
A breakthrough pancreatic cancer drug wins FDA approval and hits the clinic, raising questions over patient access.
AstraZeneca reports positive Phase III trial results for tozorakimab, a drug targeting COPD exacerbations.
A clinical trial has indicated that a drug developed through artificial intelligence may have the capacity to make patients biologically younger.
Rapid advancements in medical research and a surge in clinical trials have positioned an Alzheimer's cure as a tangible possibility for the first time.
AstraZeneca and Sanofi detail new respiratory clinical data at the #ERS26 conference.
Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.